<DOC>
	<DOC>NCT01984788</DOC>
	<brief_summary>The purpose of this study is to determine whether BCX4161 given as a daily oral prophylactic treatment is safe and effective in reducing the number of acute attacks in patients with hereditary angioedema.</brief_summary>
	<brief_title>Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas, Hereditary</mesh_term>
	<criteria>Key Written informed consent Clinical and laboratory diagnosis of Hereditary Angioedema Type I or II An average angioedema attack frequency of 1/week Acceptable birth control measures Key Concurrent use of defined treatments for prophylaxis Pregnancy or breastfeeding Clinically significant medical condition, laboratory abnormality or medical history</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Oral Prophylaxis</keyword>
</DOC>